HOUSTON, May 22, 2026
FibroBiologics, Inc. announced new preclinical data from its CYPS317 psoriasis program demonstrating durable immune modulation and sustained disease control in psoriasis animal models. The findings, presented at the Society for Investigative Dermatology (SID) 2026 Annual Meeting in Chicago, showed that the company’s human dermal fibroblast (HDF) spheroid therapy reduced disease severity, prevented relapse, and suppressed inflammatory pathways associated with chronic psoriatic disease. FibroBiologics believes the data further support CYPS317 as a differentiated cell-based therapeutic approach designed to target immune dysfunction in psoriasis without broad systemic immune suppression.
CYPS317 Demonstrates Durable Disease Control in Psoriasis Models
According to FibroBiologics, studies conducted using an imiquimod-induced psoriasis mouse model demonstrated that both HDF spheroids and single-cell fibroblast preparations reduced psoriasis severity. However, the spheroid-based therapy produced a significantly more favorable systemic safety profile by avoiding the innate immune activation observed with single-cell delivery. The company stated that this distinction may be particularly important for future systemic administration of cell-based psoriasis therapies.
In chronic-relapsing psoriasis models, booster dosing of HDF spheroids maintained therapeutic efficacy over time and prevented splenomegaly, a key marker associated with systemic immune burden and chronic inflammation. Researchers also observed significant reductions in Psoriasis Area and Severity Index (PASI) scores, normalization of monocyte-to-lymphocyte ratios, and reduced accumulation of splenic immune cells following treatment with CYPS317.
FibroBiologics noted that the findings suggest fibroblast spheroids may provide durable immunomodulatory effects capable of controlling both skin inflammation and broader immune dysregulation linked to chronic psoriatic disease.
Advertisement
Histology and Cytokine Data Support Targeted Immune Modulation
The company reported that histological analyses confirmed animals treated with fibroblast spheroids were protected against epidermal thickening and immune cell infiltration, two hallmark pathological features of active psoriasis. Cytokine profiling performed across different stages of disease progression demonstrated that single and repeated doses of HDF spheroids differentially regulated key inflammatory mediators involved in psoriasis pathogenesis.
Importantly, the cytokine data suggested that CYPS317 acts through targeted immunomodulation rather than generalized immune suppression. FibroBiologics believes this mechanism may offer an important therapeutic advantage compared with conventional systemic immunosuppressive approaches currently used for moderate-to-severe psoriasis treatment.
Psoriasis is a chronic inflammatory skin disease driven by dysregulated innate and adaptive immune responses, particularly involving the IL-23/Th17 signaling axis, which plays a central role in sustaining disease activity and chronic inflammation.
Fibroblast Spheroid Platform Expands Cell Therapy Potential
FibroBiologics stated that the CYPS317 findings further strengthen its broader fibroblast-based regenerative medicine platform, which is focused on developing therapeutics for chronic inflammatory and degenerative diseases. The company currently holds more than 270 issued and pending patents spanning multiple therapeutic areas including psoriasis, multiple sclerosis, wound healing, orthopedics, cancer, and tissue regeneration.
Company leadership emphasized that fibroblast spheroid technologies continue to demonstrate durable immunomodulatory effects across multiple chronic disease models. FibroBiologics believes these latest psoriasis findings provide important preclinical support for advancing CYPS317 toward future clinical development as a novel cell-based therapy for patients living with chronic inflammatory skin disease.
The data were presented during the SID 2026 Annual Meeting, held May 13–15, 2026, in Chicago, Illinois.
Source: FibroBiologics press release
